Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis


      • Acute outcomes after DBS are favorable.
      • Only 4.9% of individuals with PD had a 30-day non-elective readmission after DBS.
      • Comorbid disease burden was an important risk factor for readmission.
      • The readmission rate for DBS is much lower than that of many common procedures.



      Deep brain stimulation (DBS) surgery is an efficacious, underutilized treatment for Parkinson's disease (PD). Studies of DBS post-operative outcomes are often restricted to data from a single center and consider DBS in isolation. National estimates of DBS readmission and post-operative outcomes are needed, as are comparisons to commonly performed surgeries.


      This study used datasets from the 2013 and 2014 Nationwide Readmissions Database (NRD). Our sample was restricted to PD patients discharged alive after hospitalization for DBS surgery. Descriptive analyses examined patient, clinical, hospital and index hospitalization characteristics. The all-cause, non-elective 30-day readmission rate after DBS was calculated, and logistic regression models were built to examine factors associated with readmission. Readmission rates for the most common surgical procedures were calculated and compared to DBS.


      There were 6058 DBS surgeries for PD in our sample, most often involving a male aged 65 and older, who lived in a high socioeconomic status zip code. DBS patients had an average of four comorbidities. With respect to outcomes, the majority of patients were discharged home (95.3%). Non-elective readmission was rare (4.9%), and was associated with socioeconomic status, comorbidity burden, and teaching hospital status. Much higher acute, non-elective readmission rates were observed for common procedures such as upper gastrointestinal endoscopy (16.2%), colonoscopy (14.0%), and cardiac defibrillator and pacemaker procedures (11.1%).


      Short-term hospitalization outcomes after DBS are generally favorable. Socioeconomic disparities in DBS use persist. Additional efforts may be needed to improve provider referrals for and patient access to DBS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dorsey E.R.
        • Constantinescu R.
        • Thompson J.P.
        • Biglan K.M.
        • Holloway R.G.
        • Kieburtz K.
        • et al.
        Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.
        Neurology. 2007; 68: 384-386
        • Johnson S.J.
        • Kaltenboeck A.
        • Diener M.
        • Birnbaum H.G.
        • Grubb E.
        • Castelli-Haley J.
        • Siderowf A.D.
        Costs of Parkinson's disease in a privately insured population.
        PharmacoEconomics. 2013; 31: 799-806
        • Kaltenboeck A.
        • Johnson S.J.
        • Davis M.R.
        • Birnbaum H.G.
        • Carroll C.A.
        • Tarrants M.L.
        • et al.
        Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease.
        Park. Relat. Disord. 2012; 18: 321-326
        • Kowal S.L.
        • Dall T.M.
        • Chakrabarti R.
        • Storm M.V.
        • Jain A.
        The current and projected economic burden of Parkinson's disease in the United States.
        Mov. Disord. Off. J. Mov. Disord. Soc. 2013; 28: 311-318
        • Deuschl G.
        • Schade-Brittinger C.
        • Krack P.
        • Volkmann J.
        • Schafer H.
        • Botzel K.
        • et al.
        A randomized trial of deep-brain stimulation for Parkinson's disease.
        N. Engl. J. Med. 2006; 355: 896-908
        • Dafsari H.S.
        • Reddy P.
        • Herchenbach C.
        • Wawro S.
        • Petry-Schmelzer J.N.
        • Visser-Vandewalle V.
        • et al.
        Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson's disease.
        Brain Stimulat. 2016; 9: 78-85
        • Katz M.
        • Luciano M.S.
        • Carlson K.
        • Luo P.
        • Marks W.J.J.
        • Larson P.S.
        • et al.
        Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease.
        Ann. Neurol. 2015; 77: 710-719
        • Floden D.
        • Cooper S.E.
        • Griffith S.D.
        • Machado A.G.
        Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation.
        Neurology. 2014; 83: 1627-1633
        • Sobstyl M.
        • Zabek M.
        • Gorecki W.
        • Mossakowski Z.
        Quality of life in advanced Parkinson's disease after bilateral subthalamic stimulation: 2 years follow-up study.
        Clin. Neurol. Neurosurg. 2014; 124: 161-165
        • Weaver F.M.
        • Follett K.A.
        • Stern M.
        • Luo P.
        • Harris C.L.
        • Hur K.
        • et al.
        Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.
        Neurology. 2012; 79: 55-65
        • Esselink R.A.J.
        • de Bie R.M.A.
        • de Haan R.J.
        • Lenders M.W.P.M.
        • Nijssen P.C.G.
        • Staal M.J.
        • et al.
        Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial.
        Neurology. 2004; 62: 201-207
        • Schuepbach W.M.M.
        • Rau J.
        • Knudsen K.
        • Volkmann J.
        • Krack P.
        • Timmermann L.
        • et al.
        Neurostimulation for Parkinson's disease with early motor complications.
        N. Engl. J. Med. 2013; 368: 610-622
        • Willis A.W.
        • Schootman M.
        • Kung N.
        • Wang X.-Y.
        • Perlmutter J.S.
        • Racette B.A.
        Disparities in deep brain stimulation surgery among insured elders with Parkinson disease.
        Neurology. 2014; 82: 163-171
        • Zappia M.
        • Annesi G.
        • Nicoletti G.
        • Arabia G.
        • Annesi F.
        • Messina D.
        • et al.
        Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
        Arch. Neurol. 2005; 62: 601-605
        • Chiou S.-M.
        Sex-related prognostic predictors for Parkinson disease undergoing subthalamic stimulation.
        World Neurosurg. 2015; 84: 906-912
        • Hariz G.-M.
        • Limousin P.
        • Zrinzo L.
        • Tripoliti E.
        • Aviles-Olmos I.
        • Jahanshahi M.
        • et al.
        Gender differences in quality of life following subthalamic stimulation for Parkinson's disease.
        Acta Neurol. Scand. 2013; 128: 281-285
        • Kestenbaum M.
        • Ford B.
        • Louis E.D.
        Estimating the proportion of essential tremor and Parkinson's disease patients undergoing deep brain stimulation surgery: five-year data from columbia university medical center (2009-2014).
        Mov. Disord. Clin. Pract. 2015; 2: 384-387
      1. Readmissions Reduction Program (HRRP).
        • Hu K.
        • Moses Z.B.
        • Hutter M.M.
        • Williams Z.
        Short-term adverse outcomes after deep brain stimulation treatment in patients with Parkinson disease.
        World Neurosurg. 2017; 98: 365-374
        • Ramayya A.G.
        • Abdullah K.G.
        • Mallela A.N.
        • Pierce J.T.
        • Thawani J.
        • Petrov D.
        • et al.
        Thirty-day readmission rates following deep brain stimulation surgery.
        Neurosurgery. 2017; 81: 259-267
        • Chen T.
        • Mirzadeh Z.
        • Chapple K.
        • Lambert M.
        • Ponce F.A.
        Complication rates, lengths of stay, and readmission rates in “awake” and “asleep” deep brain simulation.
        J. Neurosurg. 2017; 127: 360-369
        • Sharma M.
        • Ambekar S.
        • Guthikonda B.
        • Wilden J.
        • Nanda A.
        Regional trends and the impact of various patient and hospital factors on outcomes and costs of hospitalization between academic and nonacademic centers after deep brain stimulation surgery for Parkinson's disease: a United States Nationwide Inpatient Sample analysis from 2006 to 2010.
        Neurosurg. Focus. 2013; 35: E2
        • Rumalla K.
        • Smith K.A.
        • Follett K.A.
        • Nazzaro J.M.
        • Arnold P.M.
        Rates, causes, risk factors, and outcomes of readmission following deep brain stimulation for movement disorders: analysis of the U.S. Nationwide Readmissions Database.
        Clin. Neurol. Neurosurg. 2018; 171: 129-134
        • HCUP Nationwide Readmissions Database (NRD)
        Healthcare Cost and Utilization Project (HCUP).
        • Chan A.K.
        • McGovern R.A.
        • Brown L.T.
        • Sheehy J.P.
        • Zacharia B.E.
        • Mikell C.B.
        • et al.
        Disparities in access to deep brain stimulation surgery for Parkinson disease: interaction between African American race and Medicaid use.
        JAMA Neurol. 2014; 71: 291-299
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • Coffey R.M.
        Comorbidity measures for use with administrative data.
        Med. Care. 1998; 36: 8-27
        • Shahgholi L.
        • De Jesus S.
        • Wu S.S.
        • Pei Q.
        • Hassan A.
        • Armstrong M.J.
        • et al.
        Hospitalization and rehospitalization in Parkinson disease patients: data from the national Parkinson foundation centers of excellence.
        PLoS One. 2017; 12 (e0180425)
        • Stocchi F.
        • Antonini A.
        • Barone P.
        • Tinazzi M.
        • Zappia M.
        • Onofrj M.
        • et al.
        Early DEtection of wEaring off in Parkinson disease: the DEEP study.
        Park. Relat. Disord. 2014; 20: 204-211
        • Jimenez-Shahed J.
        • Bressman S.
        • Burack M.
        • Farace E.
        • McInerney J.
        • Kirk J.
        • et al.
        RAD-PD: Registry for the advancement of DBS in Parkinson's disease.
        Mov. Disord. 2017; 32: e14